In a closely watched trial, the European Court of Justice has declared that it has no jurisdiction to make a ruling in a case involving parallel trading. The case centers on GlaxoSmithKline's efforts to block parallel traders who buy drugs at low prices in some European countries and resell them in countries where prices are higher. Experts say the decision will leave the parallel trading market in a legal limbo for years to come. Story